Hexagon Bio
Hexagon Bio, founded in 2016 and based in Menlo Park, California, uses an AI-enabled genomics, metabolomics and synthetic biology platform to mine microbial (fungal) genomes for novel cytotoxic small molecules used as next-generation antibody-drug conjugate (ADC) payloads.
Position in SVTR
Snapshot 2026-10-27- Startup SignalsRankedof 2,370new
- Life SciencesRankedof 254
- AI for ScienceRankedof 106
- Drug DiscoveryRankedof 60
About
Hexagon Bio, founded in 2016 and based in Menlo Park, California, uses an AI-enabled genomics, metabolomics and synthetic biology platform to mine microbial (fungal) genomes for novel cytotoxic small molecules used as next-generation antibody-drug conjugate (ADC) payloads. Its lead candidate HEX-360 is a HER2-targeting ADC with a novel translation-inhibitor payload.
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Investor· 5
Founders / team· 4
Funding history
- 2026-10-23Series C$62M
Investors · The Column Group, Nextech Invest, Deviation Capital, 8VC, CPP InvestmentsSource · globenewswire.com ↗
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Hexagon Bio
Hexagon Bio, founded in 2016 and based in Menlo Park, California, uses an AI-enabled genomics, metabolomics and synthetic biology platform to mine microbial (fungal) genomes for novel cytotoxic small molecules used as next-generation antibody-drug conjugate (ADC) payloads. Its lead candidate HEX-360 is a HER2-targeting ADC with a novel translation-inhibitor payload.
Series C · 2026-10
—
United States
BusinessLatest roundTotal raisedDate- LifeMine Therapeutics
A clinical-stage precision drug discovery company based on fungal genome mining, developing novel therapies in transplantation and immunology.
Series D+ · $558M · 2026-08
$558M - insitro
ML-driven drug discovery modeling high-throughput cellular data and human clinical/genomic data, with in-house pipeline and pharma partnerships
$400M
$400M - Apricity Health
Tech-driven virtual oncology care platform plus Dynamic Precision real-world data drug discovery engine, integrating patient-reported outcomes, EHRs and genomic data; serves cancer patients and care teams, academic cancer centers and pharma companies, using longitudinal patient data to find druggable adaptive resistance mechanisms and companion biomarkers.
—
China
BusinessLatest roundTotal raisedDate- NeuShen Therapeutics
Novel drugs for CNS psychiatric and neurological disorders, with the NeuChime small-molecule discovery platform and NeuGem AAV gene therapy platform; lead programs include NS-136 (M4 positive allosteric modulator) and NS-041 (KCNQ2/3 activator)
Series B · 2026-09
— - AIPher
AI-native drug discovery: proprietary drug foundation models and AI agent engine for early discovery of novel small-molecule, peptide and other drugs
Angel · 2026-09
— - Insilico Medicine
AI drug discovery company that uses generative models for target discovery and molecular design, and has advanced multiple drug candidates into clinical trials
Series D+ · $210M · 2025-03
$210M
Europe
BusinessLatest roundTotal raisedDate- Undecimal Bio
AI-driven discovery of conjugate molecules for extrahepatic targeted delivery of RNA drugs (DELiveri platform)
Seed · 2026-10
— - OutSee
AI analysis of individual genomes to predict disease biology and help drug developers find new targets
Seed · $2M · 2025-06
$2M - Basecamp Research
Trains the EDEN foundation model on proprietary biodiversity genomic data and uses AI to design proteins and in vivo cell therapies
Series C · $200M · 2026-09
$200M
Other / unspecified
BusinessLatest roundTotal raisedDate- Galux
AI plus physics-based protein/antibody design platform (GaluxDesign) for drug discovery
Series B · $58M · 2026-02
$58M - 深度细胞
Combines AI with multiscale molecular physics to build a "virtual cell world model" for disease mechanism discovery and drug design
Seed · $14M · 2026-08
$14M - Halmos Labs
AI-driven automated R&D systems for biotech and pharma that simulate experimental outcomes before wet-lab work and recommend the experiments that most reduce uncertainty
—
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
General Catalyst
40 Life Sciences deals in the last 24 months · 14 at a nearby stage · 36 in Silicon Valley
Request intro →Y Combinator
39 Life Sciences deals in the last 24 months · 10 at a nearby stage · 32 in Silicon Valley
Request intro →Andreessen Horowitz
24 Life Sciences deals in the last 24 months · 12 at a nearby stage · 22 in Silicon Valley
Request intro →Khosla Ventures
21 Life Sciences deals in the last 24 months · 10 at a nearby stage · 20 in Silicon Valley
Request intro →Thrive Capital
18 Life Sciences deals in the last 24 months · 11 at a nearby stage · 15 in Silicon Valley
Request intro →Lightspeed
17 Life Sciences deals in the last 24 months · 11 at a nearby stage · 15 in Silicon Valley
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.